Floatz logo

ROPIVACAINE

Systemic Inflammatory Response Syndrome

University of CreteSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Systemic Inflammatory Response Syndrome cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
University of Crete
Phase 4BB
Bxcl501
University of Crete
Phase 4BB
PROPOFOL
University of Crete
Phase 4BB
CISATRACURIUM ION
University of Crete
Phase 4BB
DROPERIDOL
University of Crete
Phase 4BB

View all 18 →

Same molecule, other indications

ROPIVACAINE is also rated in:

post-operative pain, non-human animalDormant
BBB
Indicative ·
76 / 100
View asset →
Knee Pain ChronicDormant
BBB
Indicative ·
76 / 100
View asset →
osteoarthritis, hipDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →